Drug intelligence / Profile preview

STM-01

Development stage: Phase 1
Lead developer: Secretome Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

STM-01 is an allogeneic cell therapy derived from neonatal cardiac progenitor cells (nCPCs), also referred to as neonatal mesenchymal stem cells (nMSCs). Developed by Secretome Therapeutics, it is designed to treat inflammatory cardiovascular diseases, specifically heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy (DCM). The therapy functions by reducing systemic and local inflammation, inhibiting cardiac fibrosis, and promoting tissue repair. STM-01 has received FDA Fast Track designation for HFpEF and is currently being evaluated in Phase 1 clinical trials (e.g., NCT06560762) to assess safety, tolerability, and preliminary efficacy via intravenous infusion.

Other names: neonatal cardiac progenitor cell therapynCPC therapyneonatal mesenchymal stem cellsnMSC

Beyond the preview

Go deeper on STM-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STM-01.

Explore the full profile